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Multifunctional Activity of the 
β-Defensin-2 during Respiratory 
Infections
Dora Patricia Rosete Olvera and Carlos Cabello Gutiérrez
Abstract
Human β-defensin-2 is a small cationic peptide that is part of the innate and 
adaptive immunity. It is expressed mainly in the epithelium and has a broad 
 spectrum of antimicrobial activity against bacteria, fungi and viruses. In addition 
to its antimicrobial activity, it has other biological functions. The alteration of the 
expression of β-defensin-2 in the respiratory epithelium has been associated with 
the pathogenesis of several respiratory diseases such as asthma, pulmonary fibrosis, 
pneumonia, tuberculosis, rhinitis, etc. The acute respiratory infections caused by 
viruses are the main cause of morbidity and mortality in the world; there are few 
studies and it is necessary to study this peptide to understand its role in the viral 
pathogenesis. In addition, it also becomes relevant in its potential to take advantage 
of its properties in the development of alternative therapies that allow the preven-
tion or treatment of viral respiratory infections.
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1. Introduction
Defensins are a family of antimicrobial peptides that are part of the innate and 
adaptive immune system. They provide protection against too broad spectrum of 
pathogens, viruses, bacteria and fungi [1]. The defensins are small cationic peptides 
of 3–4 kb, and its structure is composed of beta sheets, six cysteines joined by disul-
fide bonds. In humans, it is classified in two groups: α- and β-defensins [2, 3]. The 
β-defensin-2 (HBD2) is found in the second group and it is a peptide of 41 amino 
acids; it is expressed mainly in the epithelial cells, mucous and skin [1, 4, 5]. It was 
isolated in 1997 from skin lesions in patients with psoriasis; later, it was detected 
in the epithelium of almost entire human body [6–14]. In recent years, HBD2 has 
been considered as a multifunctional peptide with antimicrobial activity and with 
immunomodulatory functions [15–17]. On the other hand, the HBD2 is expressed 
throughout the respiratory epithelium from the mouth to the lungs; it is believed 
that this defensin has a very important role in the defense against respiratory infec-
tions [2]. The alteration of the expression of the HBD2 in the respiratory epithelium 
has been associated with the pathogenesis of several respiratory diseases such as 
asthma, pulmonary fibrosis, pneumonia, tuberculosis, rhinitis, etc. [2, 9, 17–20].
The acute respiratory infections caused by viruses are the main cause of morbid-
ity and mortality in the world, and HBD2 has got antiviral activity against some 
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respiratory viruses (influenza, respiratory syncytial virus, rhinovirus) [21–23]. 
The mechanisms of viral inactivation vary and include not only direct binding of 
the virus to the peptide but also indirect methods of inactivation via intracellular 
modulation of the viral replication, modulation of signaling pathways necessary for 
antiviral effects, and recruitment of immune cells that contribute to antiviral activ-
ity [2, 22]. This revision chapter focuses on the structural and general characteris-
tics of HBD2, multifunctional activities and expression in respiratory diseases. We 
present some studies concerning the effect of respiratory viruses and their relation-
ship with HBD2, mechanisms of action and their relevance as therapeutic agents.
2. General characteristics and classification
Defensins are a family of antimicrobial peptides that form part of the innate 
and adaptive immune system and constitute the first line of host defense against 
microorganisms. It has shown the broad antimicrobial activity spectrum against 
bacteria, fungi and viruses [1, 24].
The defensins are small cationic peptides of 28–42 amino acids, characterized 
by a β-sheet structure linked by tree disulfide bonds, which are formed by six 
cysteine residues [2, 25]. Based on the distribution of their cysteines and disulfide 
bonds, defensins are classified into two groups in humans: α- and β-defensins [1]. 
α-defensins have 29–35 amino acids and the positions of the cysteines are C1-C6, 
C2-C4 and C3-C5, while the β-defensins are composed of 38–42 amino acids with 
the positions of the cysteines of C1-C5, C2-C4 and C3-C6 [26].
The α-defensins are expressed mainly in neutrophils and called human neutrophil 
peptides with four types (HNP1–4). There are other α-defensins (HD5 and HD6), 
known as enteric defensins, that are expressed in Paneth cells in the small intestine 
[27]. The expression of HBD6 has also been confirmed in the female genitourinary 
system [1, 28].
β-defensins are mainly expressed in epithelial cells throughout the body, includ-
ing mucous membranes and skin [29–32]. Four types (HBD1–4) have been identi-
fied in humans, but several analyses indicate that there may be approximately 31 
types, of which HBD5 and 6 are expressed in epididymis with their importance in 
defense against infections. The other defensins are known only for their antimicro-
bial activity [33, 34]. The β-defensin-1 is expressed constitutively, while the other 
three (HBD2–4) are expressed by the effect of proinflammatory cytokines or during 
the infectious process [1, 28].
3. Molecular structure of β-defensin-2
The HBD2 is a small cationic peptide with a positive net charge (+6). It has 41 
amino acid residues; the complete gene is approximately 4 kb. It consists of six cys-
teines in positions 1–5, 2–4 and 3–6, joined by three disulfide bonds. Its secondary 
structure consists of an N-terminal region linked to an alpha helix, three β-strands 
arranged in an antiparallel sheet and a C-terminal region [35–37] (Figure 1). Its 
structure has an amphipathic nature, with hydrophilic and hydrophobic amino 
acids on the surface of protein; it is stabilized by the disulfide bonds, which protect 
it from degradation by proteases [38, 39]. The alpha helix is also stabilized by the 
disulfide bonds (I and V) and by the first beta sheet that has a domain (Gly-X-
CysIV), which is responsible for the native structure and the correct folding of the 
peptide [40, 41]. The N-terminal region binds to the membrane of microorganisms. 
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The specific conformation of N-terminal region of β-defensins may be important 
for the biological properties of these proteins. [37].
The C-terminal region consists mainly of cationic amino acids (lysine and 
arginine) that are distributed asymmetrically with their positive charges and are 
important in antimicrobial activity [3, 38, 40].
4. Genetic structure of β-defensin-2
The gene codify for HBD2 is located on chromosome 8p23. The gene is approxi-
mately 4 kb and composed of a 5‘and 3’ non-translatable region, two exons sepa-
rated by an intron. The first exon has 81 bp and codes for the signal peptide and the 
second exon has 238 bp and codes for a short anion segment called propeptide and 
the mature peptide [3, 25, 42]. The 5′ region of HBD2 has specific sites that bind to 
the transcription factor kB (NF-kB). In addition, there are sites that bind to other 
transcription factors such as C/EBP, and NF-IL-6, which are important for their 
expression [42–44].
The HBD2 have a polymorphic nature, and the number of copies of the gene 
varies in each individual [45]. It has been reported that there are 2–12 copies per 
diploid genome, and the number of copies is related to the level of expression. It 
has been suggested that these variations may have consequences on the function 
of immune system. Some infectious and inflammatory diseases are related to the 
number of copies of the HBD2 gene [44, 46] (Figure 2).
Figure 1. 
Secondary structure of HBD-2 that consists of an N-terminal region linked to an alpha helix, three β-strands 
arranged in an antiparallel sheet and a C-terminal region [41].
Figure 2. 
Genetic structure of HBD2. It encompasses untranslated 5 ‘and 3’ regions and two exons separated by an 
intron. The first exon codes for the signal peptide and the second exon codes for the propeptide and the mature 
peptide [3].
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5. Expression and regulation of β-defensin-2
HBD2 is expressed mainly in all the epithelia of human body (respiratory, digestive, 
urogenital, conjunctive epithelium), mucous, peripheral blood and skin. In the respira-
tory system, HBD2 is expressed in mucous from the mouth to the epithelium of the 
lungs and is induced by bacteria, fungi and virus infections and by proinflammatory 
stimuli such as interleukin 1α (IL-1α), interleukin 1β (IL-1β), tumor necrosis factor 
alpha (TNF-α), interferon gamma (IFN-γ) and interleukin IL-6 (IL-6) [29, 47–51]. 
Recently, a study showed that the cytokines IL-17 and IL-22 are produced by Th17 cells, 
which are reportedly known to regulate the expression of HBD2 on mucosal surfaces 
[32]. HBD2 is produced as a functionally inactive peptide (prepro-defensin), and to 
achieve its biological activity, it must go through a post-translational modification pro-
cess and form a mature peptide. Prepro-defensin is composed of a highly hydrophobic 
pre-peptide signal, a propeptide and the mature peptide. The prepropeptide is cut by 
proteases in the Golgi apparatus, and once removed, the mature peptide with antimi-
crobial activity is secreted on the surface of the epithelial cells [3, 52].
The regulation of the expression of the HBD2 in the respiratory epithelium involves 
multiple signaling pathways; most of these have been studied with bacterial infections. 
The bacterial proteins induce the expression of HBD2 in the respiratory epithelium 
through transcription factors (NF-kB) [53], the myeloid ELF-1-like factor (MEF) [54], 
the nuclear factor interleukin 6 (NF-IL6) [55] or the activated protein 1–3 (AP1–3) [56]. 
Signaling pathways involve mitogen-activated protein kinase (MAPKs) [49, 57, 58], 
phosphatidylinositol-3-kinase (PI3K) and protein kinase C (PKC) [59].
Another form to induce HBD2 expression is through cellular receptors, the 
respiratory epithelium expresses various receptors on its surface. Toll-like recep-
tors (TLRs) 1–6 are expressed on the epithelial surface, and in the intracellular 
vesicles, the TLR3 and TLR7–9 are expressed in the endosomes or endoplasmic 
reticulum. These receptors recognize pathogens and have a cytoplasmic domain 
that is homologous to the IL-1 receptor and is responsible for initiating intracellular 
signaling pathways. This signaling cascade includes the activation of NF-kB. This 
transcription factor promotes the gene expression that contributes to the cytokines, 
chemokines, adhesion molecules, co-stimulatory molecules release as well as the 
expression of HBD2 [60].
In a study with lung epithelial cells infected with L. pneumophila, it was 
observed that the infection induces the release of HBD2, and its expression is 
mediated by the receptors TLR2 and TLR5 and activation of MAPKs (p38, JNK) and 
transcription factors NF-kB and AP-1 [50, 57, 58, 61].
Another way to regulate the expression of HBD2 is through the interaction with 
receptors; its chemotactic property was initially discovered in different types of 
cells such as monocytes, T cells and immature dendritic cells. The activity is carried 
through the CCR6 receptor binding [32].
Other receptors involved in the regulation of the HBD2 expression are the recep-
tors for vitamin D and protease-coupled receptors (PARs) [62–65].
Nowadays, HBD2 is considered a multifunctional molecule; the ability to bind 
to several ligands suggests that there may be more receptors and signaling path-
ways still to be discovered and that may have important biological activities in the 
immune system.
6. Mechanisms of action of β-defensin-2
Several mechanisms of action have been proposed for defensins; however, 
the main mechanism of action of the HBD2 is to eliminate microorganisms 
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directly through the interaction with the microorganism membrane. The first 
step is given by the electrostatic attraction between the cationic defensin with 
positive charge and the microorganism’s membrane components with negative 
charges [37].
Components of the bacteria membrane have been identified as targets for the 
HBD2. Lipopolysaccharides are targets for Gram-negative bacteria, teichoic acid 
for Gram-positive bacteria and phospholipids for both bacteria. In Gram-negative 
bacteria, the peptides are inserted into the membrane by hydrophobic interactions. 
It is thought that it possibly involves a folding of the peptide within the structure 
of the membrane [38, 66, 67]. After the electrostatic interaction of the peptide 
with the membrane and the displacement of the lipids, the defensin is added to the 
surface of membrane. There are several modes of action that have been proposed 
to describe how defensins are oriented to form pores and how the structure of the 
membrane is altered, becomes permeable, such as cell lysis and finally results in the 
death of the microorganism (Figure 3) [3, 37, 68].
The high content of negatively charged amino acids in the membranes of 
bacteria is the main factor that makes them more susceptible to being targeted by 
defensins. The membrane of the eukaryotic cells predominates lipids with neutral 
charge without net charge, they have a high level of cholesterol, and bacteria do 
not contain cholesterol in their membranes. Cholesterol causes the membrane to 
condense and prevents the peptide from penetrating; this also has an asymmetric 
distribution of phospholipids contributing to the resistance against  defensing. 
These mechanisms explain why these peptides are not toxic in eukaryotic 
cells [69, 70].
7. Multifunctional activities of β-defensin-2
HBD2 was isolated and characterized by its antimicrobial activity. Currently, 
several studies have described different biological activities of HBD2, and it is con-
sidered as a multifunctional protein. Some of the account on its biological activities 
is given below.
Figure 3. 
Mechanisms of action of HBD2. The defensin with its positive charge is attached by electrostatic attraction to 
the membrane of the pathogen forming pores [3].
Immune Response Activation and Immunomodulation
6
7.1 Antimicrobial activities
HBD2 has a broad spectrum of activity against a wide variety of bacteria, fungi 
and viruses. The mechanism of action of this defensin begins with the interaction 
of the negative charges of the pathogen membrane, the formation of pores and 
finally the lysis of the microorganism. The variability of the composition of the 
membranes of the different pathogens explains in part the different antimicrobial 
effects [2, 22].
7.2 Innate and adaptive immunity
HBD2 is important in innate immunity and constitutes the first line of host 
defense against infections by microorganisms. Its role in adaptive immunity is 
attributed mainly to its chemotactic activity in immature dendritic cells and 
memory T lymphocytes through the CCR6 receptor [26].
Several mechanisms have been proposed for HBD2 that contributes to the 
adaptive immunity: (a) Increase in the recruitment of immature dendritic cells. 
Immature dendritic cells are recruited from circulating blood or tissue near the site 
of inflammation by chemoattractants that interact with their corresponding recep-
tors (CCR1, CCR5, CCR6). (b) Formation of defensin-antigen complexes. HBD2 
forms defensin-antigen complexes facilitating the presentation to dendritic cells. 
(c) Maturation of dendritic cells. HBD2 induced the maturation of dendritic cells 
for direct production of IL-2 or indirect production of TNF and IL-1 by monocytes 
and macrophages. (d) Recruitment of memory T cells. It facilitates the recruitment 
of memory T cells that are the effector cells of adaptive immunity [15, 26].
HBD2 contributes to unite the innate and adaptive immune response, and this 
property has been applied for the development of vaccine adjuvants, since it pro-
motes adaptive immunity when it is administered together with antigens [15, 26].
7.3 Inflammation
Inflammation is a protective reaction by the host to eliminate injurious stimuli 
(microorganism, damage cell or irritants). Some viral infections cause severe 
inflammation, and the tissue can be damaged and then it must be repaired. The 
mechanisms include the production of anti-inflammatory cytokines, lipid media-
tors, glucocorticoids, immune cell apoptosis, etc. [3].
HBD2 plays a critical role in regulating inflammation processes in the respiratory 
system and modulates the production of inflammatory cytokines and chemokines. 
An increase in local expression has been observed; but in severe cases, the HBD2 
can be detected systemically [71].
HBD-2 can promote histamine release and prostaglandin D2 production in mast 
cells, suggesting a role in allergic reactions [1, 26, 72].
7.4 Anti-inflammatory activity
HBD2 and the complement system are two important innate immune mecha-
nisms against a broad range of microorganisms. The complement is composed 
of more than 30 proteins found in the human serum, and it is activated by three 
different pathways (classical, alternative and lectin) [73, 74]. It has been described 
that HBD2 binds to C1q (first component of the complement system) and inhibits 
the classical complement pathway. HBD2 have a dual protective role not only as an 
antimicrobial agent but also to provide protection against uncontrolled activation of 
complement system [73, 75, 76].
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7.5 Immunomodulatory properties
Recently, the study of the HBD2 has focused on the modulation of the immune 
response. It has been suggested that multiple mechanisms of action may be involved 
from direct binding to the membrane of the microorganism to the union with 
different types of cellular receptors that can induce transduction signals, gene 
transcription and various signaling pathways [77]. This mechanism paves the way 
for the development of new therapies for infectious respiratory diseases.
7.5.1 Moxifloxacin/HBD2
In a study with epithelial lung cells (A549) stimulated with LPS, it was dem-
onstrated that the association of moxifloxacin/HBD2 has an anti-inflammatory 
effect. Moxifloxacin is a fluoroquinolone against Gram-positive and Gram-negative 
bacteria, which may have affected the immune system. The treatment induced a 
reduction of proinflammatory cytokines (IL-1 and IL-6). These data support the 
hypothesis of its immunomodulatory capacity of HBD2 to neutralize the compo-
nents of bacteria that induce the activation of cytokines [78].
7.5.2 Vitamin D (VitD)
VitD plays an important role for the calcium homeostasis in the bones. 
Currently, the interest has focused on the modulation of the immune response in 
fighting viral respiratory infections. Some studies show that patients with defi-
ciencies in VitD are at higher risk of suffering respiratory infections in the upper 
respiratory tract [79]. One study showed the association of polymorphisms in 
the VitD receptor and severe bronchiolitis in patients infected by the respiratory 
syncytial virus [80].
The immunomodulatory effect has been of great importance in some viral 
infections; several types of cells including epithelial cells treated with VitD induce 
the expression of the receptor and the production of antimicrobial peptides such as 
the HBD2. In the patients infected with HIV, the high levels of VitD and its recep-
tor increase the amount of IL-10 and HBD2, which are associated with a natural 
resistance to HIV infection [62].
The VitD receptor is expressed in several types of cells (monocytes, B cells, T 
cells and NK), is an endogenous immunomodulator and induces the transcription 
of the HBD2. This work shows that the expression of HBD2 is important to render 
tolerance to viral infections [62, 64].
7.5.3 PARs (receptors coupled to proteases)
It is a family of receptors coupled to the G-protein, which is formed by seven 
transmembrane domains with an amino-terminal extracellular domain and a 
C-terminal domain. PARs are activated by proteolytic cleavage in the N-terminal 
domain by serine proteases. N-terminal serves as a ligand to carry out intracellular 
signaling. They are expressed in epithelial, endothelial and immune cells such as 
leukocytes, mast cells, eosinophils, neutrophils and mastoid cells. Four types of 
receptors have been described (PAR-1–4). PAR-1, 3 and 4 are activated mainly by 
thrombin and are involved in the aggregation of platelets. PAR-2 is activated by 
trypsin, tryptase from mastoid cells, protease 3 from neutrophils and tissue fac-
tor, factor VIIa and Xa [81]. Recently, PARs have been implicated in the regulation 
of the expression of antimicrobial peptides found in epithelial cells such as defen-
sins [65, 82]. The researchers identified the expression of the HBD2 in human 
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gingiva by P. gingivalis infection. Further, proteases of the bacteria induced the 
expression of the defensin through PAR2. The authors suggest that this signaling 
pathway can lead to the development of preventive therapies in mucosal infec-
tions [65].
7.5.4 Triptolide
This is an immunosuppressive and anti-inflammatory agent that was extracted 
from an herb of Chinese origin (Tripterygium wilfordii). It decreases the expression 
of the NF-kB and genes related to inflammatory processes. This review chapter 
shows that this agent suppresses the expression of HBD2 induced by IL-1β in A549 
cells and the suppression is associated with the inhibition of NF-kB [83].
7.5.5 Neutrophilic elastase
It is a serine protease that is expressed in neutrophils and stored in their gran-
ules. It has been reported that neutrophilic elastase in the bronchial epithelium has a 
direct effect against bacteria; in addition, it can regulate the increased expression of 
the HBD2 [84].
7.5.6 Dexamethasone
It is a synthetic glucocorticoid that is used in the treatment of respiratory, 
allergic or autoimmune diseases. Its effect is to decrease the expression of proin-
flammatory cytokine genes through NF-kB. The clinical use of glucocorticoids can 
increase the susceptibility to infections by decreasing the expression of antimi-
crobial peptides such as the HBD2. In this study, they investigated the molecular 
mechanism by which dexamethasone modulated HBD2 expression in response to 
IL-1b in A549 cells and, the role of MAPKs, MKP-1, AKT, and NF-kB transcription 
factor. They demonstrated that dexamethasone suppresses  the expression of HBD2 
for this signaling pathway [83].
7.5.7 Isoleucine
Isoleucine is an essential amino acid that can induce the expression of the 
HBD2 in the epithelium. Its expression involves the activation of NF-kB/rel family 
of trans-activating factors. The authors suggest that isoleucine or analogues may 
have clinical utility as immunostimulants that could bolster the defense of the 
respiratory epithelium and mucosae [85].
7.5.8 Hyaluronic acid
When the skin epithelium suffers damage, the hyaluronic acid, which is found 
in the extracellular matrix, is fragmented and activates keratinocytes which in turn 
stimulate the HBD2 production. The induction is mediated by toll receptors (TLR2 
and TLR4) as well as other signaling pathways such as c-Fos and protein kinase C; 
thus, the epithelium is protected from infections [86].
7.5.9 Sirtuin1 (SIRT1)
It is a nicotinamide adenine dinucleotide-dependent histone deacetylase, which 
regulates several processes of the innate and adaptive immune system.  
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The anti-inflammatory properties of SIRT1 are reportedly known to show [87] that 
the infection with S. pneumoniae in alveolar epithelial cells (A549) induces HBD2 
production involving the SIRT1. Furthermore, HBD2 production induced by S 
pneumoniae is mediated by the MAPK activation (p38), and the expression of IL-8 
is regulated by the phosphorylation of ERK.
7.6 Wound repair
This process has been described in the epithelium of skin and can be achieved 
by various means, which includes the modulation of cytokines production, cell 
proliferation and migration and in some cases angiogenesis [88, 89]. It has been 
demonstrated that HBD2 is expressed in normal skin [90], and its expression 
increases when the skin is damaged or during the chronic infection [91].
Patients with diabetes mellitus suffer from skin ulcers, and the expression of 
HBD2 does not increase when compared to normal skin. The scarce expression of 
HBD2 is seen during the chronic disease. The authors supposed that high glucose 
levels inhibit the expression of HBD2 in human keratinocytes [92].
HBD2 is reportedly seen to elicit intracellular Ca+2 mobilization and increased 
keratinocyte migration and proliferation [93]. Besides, this peptide induced 
phosphorylation of EGFR, signal transducer and activator of transcription STAT1 
and STAT3. These are intracellular signaling molecules involved in keratinocyte 
migration and proliferation.
7.7 Angiogenesis
It is a process by which endothelial cells proliferate and migrate towards the 
angiogenic stimulus to form new blood vessels. This process is part of the repair of 
damaged tissues and severe inflammatory processes. The present paper demon-
strates that HBD2 stimulates the migration, proliferation and formation of capillary 
tubes of endothelial cells [94].
7.8 Cytokines and chemokines
Peripheral blood mononuclear cells when stimulated by the HBD2 induce a 
strong cytokine response. The cytokines that were detected in the highest concen-
tration were interleukin 6 (IL-6), interleukin 8 (IL-8) and interleukin 10 (IL10). 
It was also found that monocyte chemotactic protein 1 (MCP-1) induces a strong 
response and also induces RANTES, IL-1β, ENA-78 and GRO, so that the induc-
tion patterns of cytokines/chemokines can be crucial in the development and 
amplification of the immune response against pathogenic microorganisms [95].
7.9 Hypertension
It has been proven that HBD2 can regulate blood pressure and provide a new 
mechanism for the treatment of hypertension [96].
8. Respiratory diseases associated with the expression of β-defensin-2
The respiratory epithelium is the largest surface of the human body in contact 
with external medium, and it exposed to a large number of pathogens.  
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The respiratory epithelium counts upon many defense effectors and one of them is 
the production of defensins. They act as a first line of host defense against invading 
microorganism. The cells of respiratory epithelium produce four types of defensins 
(HBD1–4). HBD1 is expressed constitutively and HBD2–4 are expressed during 
infectious or inflammatory processes. HBD2 is the most expressed in all respiratory 
epithelium from the oral cavity, pharynx, larynx, trachea, serous cells and submu-
cosal glands to the lung [1, 29, 97]. Several authors have reported expression of the 
HBD2 in these tissues and also detected the protein in healthy and diseased people 
in different secretions of the body such as bronchoalveolar fluid, saliva, blood, 
plasma, milk, sputum, nasal secretions, etc. [32, 98–102].
Several studies have suggested that there is a relationship between HBD2 and the 
pathogenesis of several respiratory diseases. The increase or decrease of its expres-
sion can result in the protection or amplification of the disease.
8.1 Lung cancer
This type of disease has a high mortality rate and the treatments are very 
expensive. It is difficult to detect early stages of the disease or if the tumor is benign 
or malignant, especially in the preliminary condition. The higher concentrations of 
HBD2 in the serum of patients did not show any relation with the histopathological 
classification [103].
8.2 Pneumonia
It is a disease of the lower respiratory system that mainly affects young children and 
older adults and has a high mortality rate and a great social and economic impact due 
to long periods of hospitalization and resistance to antibiotics. The alteration of the 
immune function of the mucosa of the respiratory system in these age groups consti-
tutes a risk factor for contracting pneumonia. Bacterial infections are frequent, such 
infections lead to a serious deterioration of lung function, and are usually associated 
with persistent colonization by bacteria such as Pseudomonas aeruginosa, Haemophilus 
influenzae, Streptococcus pneumonia and Legionella pneumophila. Patients with acute 
pneumonia caused by bacterial infections have shown that the HBD2 is expressed in 
lung tissue and the concentration of the protein increases in blood and alveolar fluid 
[98, 101]. When the HBD2 levels in plasma are below 12.5 mg/ml, the patients with 
pneumonia have a high possibility of needing mechanical ventilation and development 
of new complications or death [104].
In an in vitro model, L. pneumophila induces the release of hBD-2 in A549 
cells in a manner dependent on TLR2 and TLR5. The activation of p38 MAPK and 
JNK, as well as NF-B and AP-1, is involved in the production of hBD-2 induced by 
L. pneumophila. Therefore, regulation of the release of hBD-2 by L. pneumophila 
in A549 cells appears to be determined by multiple signaling molecules and may 
contribute to host defense in Legionnaires disease. [57].
8.3 Cystic fibrosis
Cystic fibrosis is a chronic lung disease with high morbidity and mortality rates. 
It is caused by a recessive mutation in the transmembrane conductance regulator 
gene (CFTR), which is located on chromosome 7 on the apical surface of epithelial 
cells [19, 24, 105]. This mutation causes abnormal transport of chlorine ions, which 
induce an increase in the salinity of the alveolar fluid. The high salt concentration 
abrogates the antimicrobial activity of HBD2; this might explain the recurrent 
bacterial infections in the lungs of these patients [32, 105].
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Bacterial infections in patients with cystic fibrosis are very common; in the 
acute phase, the patients are infected mainly with Haemophilus influenzae and 
Staphylococcus aureus. While in the chronic phase, the infection is always caused by 
Pseudomonas aeruginosa, a Gram-negative bacterium, opportunistic and resistant to 
antibiotics [32].
The decrease in the expression and degradation of HBD2 plays an important 
role in the pathogenesis of pulmonary infection for P. aeruginosa in patients 
with cystic fibrosis [105]. They explain that in the chronic phase of infection, 
the phenotype of the bacteria changes and it loses the flagella. The flagella are 
composed of flagellin, which is a virulence factor that promotes mobility and 
adhesion. The flagellum is the ligand that triggers the signaling pathway for the 
expression of HBD2. When losing the flagella, the bacterium does not recognize 
the receptor (TLR5) of the epithelium and transcription of the gene is not 
executed through NF-kB. The bacterium causes damage to the epithelium of the 
lung producing a severe inflammatory process, with production of IL-8. IL-8 
causes the accumulation of neutrophils; later, they enter apoptosis and phago-
cytosed by macrophages. Many macrophages accumulate in the lung and secrete 
cathepsin, a cysteine protease that remodels the extracellular matrix found in 
large quantities in bronchoalveolar lavage. This enzyme degrades the disulfide 
bonds of the defensins by inactivating them, thus losing their antimicrobial 
activity [9].
The patients with cystic fibrosis and polyps showed high levels of HBD2 and 
TLR2 expression with an increase in IL-8 [106]. In nasal epithelium of patients with 
CF, HBD2 is not upregulated in response to inflammatory stimuli. The higher levels 
of inflammatory markers were seen but without any correlation with the expression 
of HBD2. They explain that the epithelium of patients with cystic fibrosis is chroni-
cally exposed to inflammatory stimuli and lost the capacity to upregulate defensin 
synthesis. The inflammatory stimuli may not be the sole inducers of defense expres-
sion [107].
8.4 Chronic obstructive pulmonary disease (COPD)
COPD is an inflammatory disease of the respiratory tract that is characterized 
by recurrent infections, severe inflammation and is associated with a reduction of 
airflow and a decrease in lung function [108]. The main environmental risk factor 
is smoking; some authors suggest that tobacco smoke inhibits the activation of 
the host’s innate immune system. The in vitro studies with respiratory epithelium 
exposed to tobacco smoke are reported to inhibit the expression of HBD2 when 
infected with bacterium [109]. COPD patients who smoke have lowered basal 
hBD-2 expression in the epithelial cells of the central airways, which correlates with 
the amount of cigarette pack years. The decreased HBD2 expression is associated 
with current or former  smoking, which makes the population more susceptible 
towards infections by microorganisms [108, 110].
Moreover, genetic factors can contribute to the progression of the disease. The 
variation in the number of copies of HBD2 gene in epithelial cells is associated with 
the pathogenesis of the disease [110]. Moreover, genetic factors can contribute to 
the progression of the disease. The variation in the number of copies of HBD2 gene 
in epithelial cells is associated with the pathogenesis of COPD. In this study showed 
a significantly higher proportion of the patients with severe COPD had high diploid 
β-defensin copy numbers (five or more) compared with the control sample.
In another study, the expression of HBD2 in peripheral lung tissue in patients 
with COPD is elevated and associated with the habit of smoking and with the high 
levels of IL-8 as well as severity of the disease [111].
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8.5 Allergic rhinitis (AR)
AR is an inflammatory disorder that occurs in the nasal mucosa and triggered by 
the exposure to allergens (mites, pets, insects, pollen, latex items, tobacco particles, 
ozone, nitrogen oxide, sulfur dioxide, aspirin, etc.) producing inflammation medi-
ated by IgE. Clinically, it is characterized by symptoms such as rhinorrhea, sneez-
ing, nasal congestion and itching. These symptoms worsen a person’s productivity 
and quality of life and cause sleep disturbances, fatigue or depression. Although it 
occurs more frequently in young children, adults are affected as well [18].
Studies with tonsil tissue (lymphocytes) and pharyngeal epithelial cells from 
patients with allergic rhinitis found a reduction in the expression of HBD2. When 
cells are exposed to Th2 cytokines (IL-4, IL-5 and IL-13) and histamine in vitro, 
they also cause a decrease in the expression of HBD2. Therefore, patients with 
allergic rhinitis are more susceptible to respiratory infections and severe exacerba-
tions [112–114].
8.6 Rhinosinusitis
Rhinosinusitis is characterized by the presence of at least two respiratory symp-
toms, nasal obstruction and nasal discharge, wherein the presence or absence of 
nasal polyps is seen. In one study, the sinonasal epithelial cells of patients with rhi-
nosinusitis with nasal polyps showed a decrease in the expression of β-defensin-2 in 
response to the presence of IL-4 and IL-13 [114–116].
8.7 Otitis media
It is a very common disease mainly affecting the young children under 3 years of 
age having episode of otitis media. The pathogenesis of the disease is multifactorial, 
and among the most important factors are viral infections (respiratory syncytial virus, 
rhinovirus, influenza A, adenovirus) and bacterial infections (Streptococcus pneu-
moniae, nontypeable Haemophilus influenzae (NTHI), and Moraxella catarrhalis). The 
acute illness resolves quickly but the chronic or recurrent disease can cause hearing loss 
[39, 117].
The epithelial cells of the middle ear express HBD2, and two signaling pathways 
have been described. HBD2 expression is induced by pro-inflammatory stimuli 
such as interleukin 1 alpha (IL-1a), tumor necrosis factor alpha (TNF-a), and 
lipopolysaccharide (LPS). Their transcriptional activation is mediated through an 
Src-dependent Raf-MEK1/2-ERK signaling pathway [119]. The other known route 
is when the bacterium is recognized by the TLR2 of epithelial cells through the 
MyD88-IRAKI-TRAF6-MKK3/6-p38 MAP kinase signal transduction pathway 
[117, 118].
8.8 Asthma
It is a common chronic obstructive disease characterized by obstruction, hyper-
reactivity and inflammation. It affects all age groups throughout the world and has 
high morbidity and mortality rates [119]. Epidemiological studies indicate that the 
pathogenesis of asthma is multifactorial. The viral respiratory infections are the 
main cause of exacerbations or asthma attacks; influenza viruses, parainfluenza, 
rhinovirus and respiratory syncytial are those that have been identified more 
frequently [120, 121].
The mechanisms that explain how viruses cause or exacerbate asthma are diverse 
and some are not yet fully characterized. Recent studies indicate that HBD2 may 
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play an important role in the pathogenesis of asthma. Some mechanisms have been 
suggested to explain the exacerbations of asthma such as (a) patients with asthma 
develop a TH2 type response; it induced the production of cytokines (IL-4, IL-5, 
IL-13) that inhibit the production of HBD2, causing susceptibility to infections 
[122]. (b) HBD2 induces the activation and degranulation of mastoid cells that 
release histamine and prostaglandins, substances that increase asthma exacerba-
tions [26].
8.9 Recurrent respiratory papillomatosis
It is a disease in the respiratory tract caused by infection with human papil-
loma virus. The papilloma virus belongs to the Papovaviridae family. It is a circular 
double-stranded DNA virus and has no envelope, and its genome is 7200–8000 bp. 
There are more than 100 serotypes, which due to their oncogenic capacity are 
divided into high risk and low risk [123].
The disease characterized by abnormal proliferation of epithelial keratinocytes 
forming a papilloma. It occurs more frequently in the larynx but might spread to the 
trachea or even lungs. It is common in children 2–4 years of age and in children over 
12 years of age and in young adults. The first symptom is progressive dysphonia, 
with symptoms of variable respiratory obstruction, dyspnea and stridor. Some 
patients have spontaneous remission and others may have a very rapid growth that 
may require multiple surgical procedures or cause obstruction resulting in death. 
Papilloma viruses have a high morbidity rate because of its recurrence, and there are 
no satisfactory treatments [124, 125].
The serotypes of papilloma that have been found with higher frequency are the 
serotypes of low risk 6 and 11; nevertheless, a 2% can be infected with other sub-
types like the 16 and 18 of high risk, but these are associated with transformation of 
cells causing carcinoma [123].
The expression of HBD2 in samples of papillomavirus induced lesions in patients 
with recurrent respiratory papillomatosis, and its association with IL-8 [126] was 
studied. The lesions showed high levels of HBD2 expression, and the inflammatory 
process was not significant. Despite the higher expression of HBD2 in the deep-
seated tissues, the persistence of the virus leads to the disease progression. They 
suggest that HBD2 can serve as a signaling molecule to induce the adaptive immune 
response against viral infection with acceptable inflammatory events.
8.10 Diffuse panbronchiolitis (DP)
DP is a disease with chronic inflammation in the bronchioles of respiratory sys-
tem. The immune cells are activated, and neutrophils are found in large quantities 
and activate T lymphocytes. There are often bacterial infections (P. aeruginosa and 
H influenzae). The pathogenesis of this disease is not clear; but recently, HBD2 has 
been implicated. In a study with patients with DP, high levels of HBD2 in bronchoal-
veolar fluid and plasma were found, suggesting that it could play an important role 
in the defense against infections. The levels of HBD2 in BAL fluid may be a useful 
marker of airway inflammation in patients with DPB [127].
8.11 Tuberculosis
Tuberculosis is one of the most frequent infectious diseases that cause more 
deaths; its incidence is still a global health problem. Mycobacterium tuberculosis is 
the causative agent of tuberculosis, and it can cause a progressive disease or a latent 
infection. It has been reported that a third part of the population is latently infected 
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and 10% have active disease. There are many difficulties due to highly resistant 
strains and fewer therapeutic agents [128].
However, HBD2 is suggested to play an important role in the control of the dis-
ease by direct inactivation of the bacteria or as an immunostimulant in vaccines. This 
bacterium mainly infects macrophages and lung epithelial cells. The in vitro studies 
have shown that M. tuberculosis induces the expression of HBD2 in human lung 
epithelial cells (A549) and is associated with the destruction of bacteria [129, 130].
The transfection of monocytes derived from macrophages with the HBD2 gene 
increases the ability to control the growth of M tuberculosis when compared with 
non-transfected cells [131]. Children infected with M. tuberculosis present high 
concentrations of HBD2 in bronchoalveolar lavage suggesting its involvement in the 
pathogenesis of disease.
Results are favorable in animal model studies in mice, mice were vaccinated with 
DNA vaccines (gene encoding β-defensin-2 and antigens of M tuberculoisis) and 
months later were challenged with M tuberculoisis strains. The level of protection 
was evaluated by survival, and tissue damage. DNA vaccines showed protection with 
significant higher survival and less tissue damage in the mice [132]. When a person is 
infected with M. tuberculosis, the microenvironment is reduced in oxygen; this trig-
gers the expression of the vitamin D receptor and HBD2 inhibits the growth bacteria. 
The lack of local oxygen benefits the macrophage for its elimination.
Other signaling pathways that have been discovered are in monocytes through 
the CD40L and IFN receptors that converge in the activation of vitamin D. HBD2 is 
expressed and acts against the bacterium M. tuberculosis [134].
8.12 Sepsis
The infectious diseases can cause severe sepsis and the patient’s immune system 
to suffer drastic changes. This study investigated the concentration and the expres-
sion of HBD2 in peripheral whole blood cells from patients with severe sepsis. They 
detected that the peripheral blood cells expressed a decrease in the expression of 
HBD2. The patient serum showed higher concentrations of HBD2. The patients with 
severe sepsis have severe inflammatory processes and the proinflammatory cytokines 
are at high concentrations (IL-1 and TNF); these cytokines also induce the expression 
of HBD2. It is suggested that these cytokines may be involved in the overproduction 
of HBD2 in the blood of patients with sepsis. The decreased HBD2 induced in periph-
eral blood cells was not associated with decreased plasma levels, suggesting that 
peripheral blood cells do not represent the exclusive source of released protein [135].
9. Antiviral activity of β-defensin-2 in respiratory infections
The HBD2 was initially studied as an antibacterial peptide, and its antiviral 
activity has been recently demonstrated. The notion was that it only acted in envel-
oped viruses, but other studies have proven that they also act against naked viruses 
and any type of genome DNA, RNA and retroviruses. The mechanisms of antiviral 
inactivation have been classified as direct and indirect. The direct ones occur when 
HBD2 binds to the viral membrane by electrostatic attraction, causing pore forma-
tion and lysis of microorganism. The indirect mechanism occurs when it inactivates 
an intracellular pathway of the virus replication cycle or when there is recruitment 
of immune cells that contribute to their antiviral activity [2].
Acute respiratory infections caused by viruses are very common, causing high 
rates of mobility and mortality. There are few studies that relate to HBD2 and viral 
infection, and some of them are presented in the following paragraphs.
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9.1 Influenza virus
The influenza virus belongs to the Orthomyxoviridae family and renders acute 
respiratory infection affecting mainly children and adults. It is an RNA virus, envel-
oped and has the ability to mutate rapidly, causing epidemics and pandemics [136].
Influenza virus induces the production of HBD2 in the epithelial cells of the 
respiratory tract in vivo and in vitro [137]. In the in vitro study with infected MDCK 
cells with influenza virus, recombinant murine β-defensin-2 prevents infection by 
blocking the entry of the virus. The lungs of murine model infected with influenza 
virus showed an increased expression of β-defensin and therefore confer protection 
against infection [21, 138].
9.2 Respiratory syncytial virus (VSR)
This virus belongs to the family Paramyxoviridae and affects principally infants, 
young children and older adults causing bronchiolitis and pneumonia. VSR has a 
high rate of morbidity and mortality having RNA enveloped virus of negative sense. 
There are no vaccines available and only fewer antivirals available which have been 
seen ineffective [22, 139].
The human lung cells (A549) infected with RSV expressed HBD2 [140]. The 
expression of the peptide depends on the activation of NF-kB and the action of 
TNF produced by the virus. The elimination of the virus is due to damage to the 
membrane.
9.3 Adenovirus
The adenoviruses belong to the Adenoviridae family; 51 serotypes divided into 
six species have been recognized (HAd A-F). Species B, C and E produce respiratory 
infections. Adenoviruses are double-stranded linear DNA viruses, lack envelope 
and replicate in the nucleus, and their genome has a size of 36 kb. These viruses 
spread rapidly in closed environments such as military camps, orphanages, board-
ing schools and prisons. The acute respiratory infections are transmitted mainly by 
aerosols and by direct inoculation through fingers. Although this disease is benign 
and with little severity, the infection might be severe in immunosuppressed patients 
afflicted with HIV and with kidney transplants. The HBD2 inactivates the infection 
for adenovirus in vitro; the mechanisms of action are not yet known due to lack of in 
vivo studies [140].
9.4 Rhinovirus
The rhinovirus is the main cause of the common cold belonging to 
Picornaviridae family. They are small, single-chained, naked RNA viruses. 
Respiratory infections caused by rhinoviruses are associated with asthma exacerba-
tions in children and adults. Rhinovirus infection in the A549 cells (human lung 
cells) and bronchial epithelial cells induces the expression of HBD2. The virus 
replication appears essential for the expression of peptide [141].
10. Conclusions
Initially, β-defensin-2 was considered an antimicrobial peptide. The advance 
in the study of these molecules has made it possible to know that β-defensin-2 is a 
peptide with multiple functions. However, its role in the pathology of respiratory 
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diseases is unclear. During the infectious processes of the respiratory epithelium, 
HBD2 is expressed by the effect of the infection, and it has been described that it 
may be closely associated with the severity of the disease. The study of HBD2 dur-
ing viral respiratory infections is unclear, so it is necessary to continue investigating 
the role of this molecule in the immune response activated by viral infections.
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